Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash & Equivalents: 2011-2025

Historic Cash & Equivalents for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to $61.4 million.

  • Adma Biologics' Cash & Equivalents fell 29.20% to $61.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year decrease of 29.20%. This contributed to the annual value of $103.1 million for FY2024, which is 100.86% up from last year.
  • Latest data reveals that Adma Biologics reported Cash & Equivalents of $61.4 million as of Q3 2025, which was down 32.01% from $90.3 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Cash & Equivalents peaked at $103.1 million during Q4 2024, and registered a low of $34.4 million during Q3 2021.
  • In the last 3 years, Adma Biologics' Cash & Equivalents had a median value of $71.6 million in 2025 and averaged $73.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first slumped by 42.34% in 2021, then soared by 112.57% in 2023.
  • Over the past 5 years, Adma Biologics' Cash & Equivalents (Quarterly) stood at $51.1 million in 2021, then skyrocketed by 69.36% to $86.5 million in 2022, then tumbled by 40.65% to $51.4 million in 2023, then spiked by 100.86% to $103.1 million in 2024, then fell by 29.20% to $61.4 million in 2025.
  • Its last three reported values are $61.4 million in Q3 2025, $90.3 million for Q2 2025, and $71.6 million during Q1 2025.